Lupin gets USFDA's approval for Tiotropium Bromide Inhalation Powder

21 Jun 2023 Evaluate

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, a generic equivalent of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule of Boehringer Ingelheim Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India. Tiotropium Bromide Inhalation Powder (Spiriva HandiHaler) had estimated annual sales of $1,264 million in the U.S. (IQVIA MAT March 2023).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2166.60 0.50 (0.02%)
21-Jan-2026 12:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.70
Dr. Reddys Lab 1163.00
Cipla 1373.30
Zydus Lifesciences 879.95
Lupin 2166.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×